BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
156 hedge funds and large institutions have $134M invested in bluebird bio in 2024 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 61 increasing their positions, 40 reducing their positions, and 54 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
41% less call options, than puts
Call options by funds: $1.48M | Put options by funds: $2.49M
54% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 54
Holders
156
Holding in Top 10
–
Calls
$1.48M
Puts
$2.49M
Top Buyers
| 1 | +$7.93M | |
| 2 | +$4.65M | |
| 3 | +$3.62M | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.49M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.21M |
Top Sellers
| 1 | -$13.4M | |
| 2 | -$7.85M | |
| 3 | -$7.24M | |
| 4 |
Norges Bank
Oslo,
Norway
|
-$5.51M |
| 5 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$4.35M |